Soome - soome - Fimea (Suomen lääkevirasto)

pfizer oy - ispaghula husk - rakeet - ispaghula (psylliumin siemenet)

Soome - soome - Fimea (Suomen lääkevirasto)

pfizer oy - ispaghula husk - rakeet - ispaghula (psylliumin siemenet)

Soome - soome - Fimea (Suomen lääkevirasto)

ferring lääkkeet oy ferring lääkkeet oy - desmopressini acetas - tabletti, kylmäkuivattu - 60 mikrog - desmopressiini

Soome - soome - Fimea (Suomen lääkevirasto)

ferring lääkkeet oy ferring lääkkeet oy - desmopressini acetas - tabletti, kylmäkuivattu - 120 mikrog - desmopressiini

Soome - soome - Fimea (Suomen lääkevirasto)

ferring lääkkeet oy ferring lääkkeet oy - desmopressini acetas - tabletti, kylmäkuivattu - 240 mikrog - desmopressiini

Euroopa Liit - soome - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Euroopa Liit - soome - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - ripulilääkkeet, suoliston antiinflammatory / antiinfective agents - truberzi on tarkoitettu aikuisille ärtyvän suolen oireyhtymän ja ripulin hoitoon (ibs d).

Euroopa Liit - soome - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Soome - soome - Fimea (Suomen lääkevirasto)

mcneil, a division of janssen- cilag oy - loperamidi oxidum monohydricum - tabletti - 1 mg - loperamidioksidi

Soome - soome - Fimea (Suomen lääkevirasto)

copyfarm a/s - lamotriginum - dispergoituva tabletti - 5 mg - lamotrigiini